Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Castration-Resistant Prostate Cancer Patients 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 134Carboplatin 129Bevacizumab 86Gemcitabine 45pembrolizumab 37olaparib 33Cisplatin 30liposomal doxorubicin 29Docetaxel 29Cyclophosphamide 29Topotecan 28niraparib 27Taxes 20Etoposide 18Filgrastim 16Doxorubicin 16Immunoglobulin G 15Disulfides 15apatinib 12Letrozole 12Albumin-Bound Paclitaxel 12Drug Therapy 11fluzoparib 10fludarabine 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 10durvalumab 9Nivolumab 9pazopanib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Neoplasms × irofulven × Clear all
NCT00019552 2013-06-20

Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡